Literatürde Metabolik Cerrahi
Literatürde Metabolik Cerrahi
Anasayfa Metabolik Cerrahi Literatürde Metabolik Cerrahi
Bilgi Almak İçin
Formumuzu Doldurun!
Literatürde Metabolik Cerrahi

1) The World Health Report. 2002. Reducing Risks, Promoting Healthy Life: 2002. (Geneva, Switzerland: World Health Organization).

2) Hossain P, et al. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007; 356: 213–215.

3) Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635–643.

4) Kortt MA, et al. A review of cost-of-illness studies on obesity. Clin Ther 1998; 20: 772–779.

5) Bray GA, et al. Medicinal strategies in the treatment of obesity. Nature 2000; 404: 672-7.

6) McCullough ML, et al. Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiol Biomarkers Prev 2011; 20(6): 1089-97.

7) Venkat NKM, et al. Diabetes–a common, growing, serious, costly and potentially preventable public health problem. Diabetes Res Clin Pract 2000; 50(2): 77-84.

8) King H, et al. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.

9) Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.

10) Onat A, et al. Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadol Kardiyol Derg 2006; 6(4): 314-21.

11) Oğuz A, et al. Obesity and abdominal obesity; an alarming challenge for cardio-metabolic risk in Turkish adults. Anadol Kardiyol Derg 2008;8(6):401-6.

12) Onat A, et al. Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks. Am J Hypertens 2008; 21(8): 890-5.

13) Erem C, et al. Prevalence of metabolic syndrome and associated risk factors among Turkish adults: Trabzon MetS study. Endocrine 2008; 33: 9-20.

14) Onat A, et al. Elevated LDL-cholesterol level predicts diabetes in centrally obese women but not men: relative roles of insulin resistance and central obesity. Circ J 2007; 71(9): 1463-7.

15) Duman BS, et al. Association of Resistin Gene 3′-Untranslated Region EX4-44G–>A Polymorphism with Obesity- and Insulin-Related Phenotypes in Turkish Type 2 Diabetes Patients. Rev Diabet Stud. 2007; 4(1): 49-55.

16) Pories WJ. Diabetes: The evolution of a new paradigm. Ann Surg 2004; 239(1): 12-13.

17) King H, et al. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab Care 1998; 21: 1414-1431.

18) Pories W, et al. “Who would have thought it? An operation proves to be the most effective therapy for adult onset Diabetes Mellitus”. Ann Surg 1995; 222(3): 339-352.

19) Scheen AJ, et al. The place of bariatric surgery in the management of the obese type 2 diabetic patient. Int Diab Monitor 1998; 10: 1-7. 20) Rubino F, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240:236-242.

21) Adami GF, et al. Recovery of insulin sensitivity in obese patients at short term after biliopancreatic diversion. J Surg Res 2003; 113: 217-221.

22) Dhabuwala A, et al. Improvement in co-morbidities following weight loss from gastric bypass surgery. Obes Surg 2000; 10: 428-435.

23) MacDonald KG Jr, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-220.

24) Scopinaro N, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow up study. Diabetes Care 2005; 28: 2406-2411.

25) Scopinaro N, et al.Long-Term Control of Type 2 Diabetes Mellitus and the Other Major Components of the Metabolic Syndrome after Biliopancreatic Diversion in Patients with BMI < 35 kg/m2 . Obesity Surgery 2007; 17: 185-192.

26) Rubino F, et al. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes. Ann Surg 2004;239:1–11.

27) DePaula AL, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008; 22: 706–716.

28) AC Ramos, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m2 (LBMI). Obes Surg 2009; 19(3): 307-312.

29) Santoro S. Adaptive and neuroendocrine procedures: A new pathway in bariatric and metabolic surgery. Obes Surg; 2008: 18:1343-45.

30) Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007; 107(3): 6-9.

31) Boyle PJ, et al. Application of incretin mimetics and Dipeptidyl Peptidase IV inhibitors in managing type 2 diabetes mellitus. J Am Osteopath Assoc 2007; 107(3):10-16.

32) Hou, J, et al. High-level expression of fusion protein containing 10 tandem repeated GLP-1 analogs in Yeast Pichia pastoris and its biological activity in a diabetic rat model. Biosci Biotechnol Biochem 2007; 71(6): 1462-1469.

33) Mason EE. Ilial transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg 1999; 9: 223-228.

34) Schauer PR, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467-484.

35) Clements RH, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004; 70: 1-4.

36) Cummings DE, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30.

37) Atkinson RL, et al. Appetite suppressant activity in plasma of rats after intestinal bypass surgery. Am J Physiol 1982; 243: 60-64.

38) Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-1602.

39) Aylwin SJB. Gastrointestinal surgery and gut hormones. Curr Opin Endocrinol Diabetes 2005; 12: 89-98.

40) Imamura M. Effects of surgical manipulation of the intestine on peptide YY and its physiology. Peptides 2002; 23:403-407.

41) Le Roux CW, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114.

42) Drucker DJ. Incretin-based therapies: a clinical need filled by unique metabolic effects. Diabetes Educ 2006; 32(Suppl 2); 65-71.

43) DeFronzo RA, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.

44) Buse JB, et al. For the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.

45) Kendall DM, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28:1083-1091.

46) NIH Conference: Gastrointestinal surgery for severe obesity. Ann Intern Med 1991; 115: 959-61.

47) Brolin RE, et al. Long-limb gastric bypass in the superobese: a prospective randomized study. Ann Surg 1992; 215: 387-95.

48) MacLean LD, et al. Late outcome of isolated gastric bypass. Ann Surg 2000; 231: 524 –528.

49) Wittgrove A, et al. Laparoscopic gastric bypass, Roux-en-Y: 500 patients: technique and results, with 3–60 month follow-up. Obese Surg 2000; 10: 233–39.

50) Higa K, et al. Laparoscopic Roux-en-Y gastric bypass for morbid obesity. Arch Surg 2000; 135:1 029 –34.

51) Schauer P, et al. Outcomes after laparoscopic gastric bypass for morbid obesity. Ann Surg 2000; 232: 515–29.

52) DeMaria EJ, et al. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 2002; 235: 640–647.

53) MacDonald KG Jr, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:213-20.

54) Flum DR, et al. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg 2004;199:543-51.

55) Christou NV, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416-23.

56) Zhang W, et al. Factors influencing survival following surgical treatment of obesity. Obes Surg 2005; 15: 43-50.

57) Sjöström L,et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52.

58) Greenway SE, et al. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 2002; 137: 1109-17.

59) Snow LL, et al. The effect of Roux-en-Y gastric bypass on prescription drug costs. Obesity Surgery 2004; 14: 1031-35.

60) Pories WJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-year follow-up. Am J Clin Nutr 1992; 55: 582-5.

61) Cohen R, et al. Laparoscopic Roux-en-Y gastric bypass for BMI < 35 kg/m(2): a tailored approach. Surg Obes Relat Dis 2006; 2:401-4.

62) Schauer PR, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467-85.

63) Saber AA, et al. Bariatric Surgery: The Past, Present, and Future. Obes Surg 2008; 18: 121–128.

64) Cohen RV, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of two cases. Surg Obes Relat Dis 2007; 3(2): 195-7.

65) Rubino F, et al. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002; 236: 554-9.

66) Patriti A, et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840-8.

67) Hickey MS, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 1998; 227: 637-44.

68) Sirinek KR, et al. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery 1986; 100: 781-7.

69) Pories WJ. Why does the gastric bypass control type 2 diabetes mellitus? Obes Surg 1992; 2: 303-13.

70) Holdstock C, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177-83.

71) Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001; 24(3): 454-9.

72) Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010; 375:408-18.